Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Credit Suisse Maintains Outperform on Avidity Biosciences, Raises Price Target to $35

Credit Suisse analyst Judah Frommer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price target from $33 to $35.
byBenzinga Newsdesk
December 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Credit Suisse analyst Judah Frommer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price target from $33 to $35.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Jefferies Says Bed Bath & Beyond Bankruptcy Risk Is Priced In, Given BBBY’s <$350M Market Cap And High Short Interest, We Believe The Potential To Capture An Incremental ~$800M In Gross Proceeds From The Equity Deal Could Lead To A Spike In Shares..

By Happy Mohamed
February 8, 2:28 PM
Bed Bath & Beyond Bankruptcy Risk Is Priced In, Jefferies Says. Given BBBY's <$350M market cap and high short interest, we believe the potential to capture an incremental ~$800M in gross proceeds from the

BBBY